Importer of Controlled Substances; Notice of Application, 389 [05-73]
Download as PDF
<![CDATA[
389
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–72 Filed 1–3–05; 8:45 am]
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on October
28, 2004, Cambrex Charles City, Inc.,
1205 11th Street, Charles City, Iowa
50616, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in Schedule
II.
The company plans to import the
phenylacetone to manufacture
amphetamine for distribution to its
customers.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections or
requests for hearing may be addressed,
in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, United States
Department of Justice, Washington, DC
20537, Attention: DEA Federal Register
Representative, Office of Liaison and
Policy (ODLR) and must be filed no later
than February 3, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–68 Filed 1–3–05; 8:45 am]
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–73 Filed 1–3–05; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 21, 2004, and
published in the Federal Register on
August 10, 2004, (69 FR 48521–48522),
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as a bulk
manufacturer of the basic classes of
controlled substances listed below:
Schedule
Drug
Marihuana (7360) ...........................
Tetrahydrocannabinols (7370) .......
I
I
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cayman Chemical Company to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cayman Chemical
Company to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 28, 2004, and
published in the Federal Register on
July 13, 2004, (69 FR 42067–42068),
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed below:
Drug
Tetrahydrocannabinols (7370) .......
Dihydromorphine (9145) ................
Hydromorphone (9150) ..................
Fentanyl (9801) ..............................
Schedule
I
I
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–66 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\04JAN1.SGM
04JAN1
]]>Agencies
[Federal Register Volume 70, Number 2 (Tuesday, January 4, 2005)]
[Notices]
[Page 389]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-73]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on October 28, 2004, Cambrex Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as an importer of
Phenylacetone (8501), a basic class of controlled substance listed in
Schedule II.
The company plans to import the phenylacetone to manufacture
amphetamine for distribution to its customers.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances may
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such comments or objections or requests for hearing may be
addressed, in quintuplicate, to the Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration, United
States Department of Justice, Washington, DC 20537, Attention: DEA
Federal Register Representative, Office of Liaison and Policy (ODLR)
and must be filed no later than February 3, 2005.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substances in
Schedule I or II are and will continue to be required to demonstrate to
the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b),
(c), (d), (e) and (f) are satisfied.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-73 Filed 1-3-05; 8:45 am]
BILLING CODE 4410-09-P
